Catherine H Castonguay

Nov 6, 2023 | cell.com | Allen M Vong |Catherine H Castonguay |Noah Silverstein |Olivia Kugler-Umana

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Sep 29, 2023 | cell.com | Allen M Vong |Catherine H Castonguay |Noah Silverstein |Olivia Kugler-Umana

Highlights•ThCTL effectors develop in the infected tissue from CD4 effectors•ThCTL development from CD4 effectors requires local antigen presentation in tissue•CD28 co-stimulation or a specific APC type is not required•ThCTL development requires infection-generated type I IFN that induces IL-15SummaryCytotoxic CD4 T cell effectors (ThCTLs) kill virus-infected major histocompatibility complex (MHC) class II+ cells, contributing to viral clearance.

Sep 29, 2023 | cell.com | Allen M Vong |Catherine H Castonguay |Noah Silverstein |Olivia Kugler-Umana

Highlights•ThCTL effectors develop in the infected tissue from CD4 effectors•ThCTL development from CD4 effectors requires local antigen presentation in tissue•CD28 co-stimulation or a specific APC type is not required•ThCTL development requires infection-generated type I IFN that induces IL-15SummaryCytotoxic CD4 T cell effectors (ThCTLs) kill virus-infected major histocompatibility complex (MHC) class II+ cells, contributing to viral clearance.